Zobrazeno 1 - 10
of 7 726
pro vyhledávání: '"TOFACITINIB"'
Publikováno v:
Exploration of Immunology, Vol 4, Iss 6, Pp 770-779 (2024)
Immunotherapy, a primary anti-neoplastic treatment, exploits the patient’s immune system to kill neoplastic cells by modulating immune checkpoints such as cytotoxic T-lymphocyte antigen 4 and programmed cell death 1. Despite an apparent anti-neopla
Externí odkaz:
https://doaj.org/article/eea866b22cdc4e7a883c8c62b3b5ef24
Autor:
Boulos Haraoui, Majed Khraishi, Denis Choquette, Isabelle Fortin, Cassandra D. Kinch, Corina Galos, Patrice Roy, David Gruben, Julie Vaillancourt, John S. Sampalis, Edward C. Keystone
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 6, Pp 1629-1648 (2024)
Abstract Introduction ORAL Surveillance, a post-authorisation safety study of patients with rheumatoid arthritis (RA) enriched for cardiovascular (CV) risk, demonstrated increased risk of major adverse CV events (MACE) and malignancies (excluding non
Externí odkaz:
https://doaj.org/article/214537ed140d4f4797dda101eed1469c
Publikováno v:
Pediatric Rheumatology Online Journal, Vol 22, Iss 1, Pp 1-6 (2024)
Abstract Background Juvenile Dermatomyositis (JDM) is a rare disorder with subtypes associated with different myositis-specific antibodies (MSAs) including anti-MDA5. Hepatic involvement in JDM is rare and has not previously been documented in anti-M
Externí odkaz:
https://doaj.org/article/1c24e99755ed49e89859c2917676be6c
Autor:
Yui Imai, Takafumi Yorozuya, Taku Hatakeyama, Takumi Nishimaki, Tomoyuki Takahashi, Tatsuru Ishikawa, Shun Kondoh, Yuichiro Asai, Yuki Mori, Atsushi Saito, Hirotaka Nishikiori, Michiko Hosaka, Hirofumi Chiba
Publikováno v:
Journal of Medical Case Reports, Vol 18, Iss 1, Pp 1-7 (2024)
Abstract Background Clinical amyopathic dermatomyositis is characterized by cutaneous symptoms but lacks muscle symptoms. Anti-melanoma differentiation-associated gene 5 antibodies are frequently found in Japanese patients with clinical amyopathic de
Externí odkaz:
https://doaj.org/article/87d6510f10904f17b0858a54e8ca8d17
Autor:
Giovanni Adami, Giovanni Orsolini, Maurizio Rossini, Anna Fratucello, Angelo Fassio, Ombretta Viapiana, Elena Fracassi, Riccardo Bixio, Davide Gatti
Publikováno v:
BMC Rheumatology, Vol 8, Iss 1, Pp 1-10 (2024)
Key-points Bone turnover makers (P1nP, B-ALP, CTX), bone modulators (Dkk1, sclerostin) and BMD were measured prospectively in rheumatoid arthritis patients treated with tofacitinib. Sclerostin increased significantly after treatment with tofacitinib,
Externí odkaz:
https://doaj.org/article/d35e056c86f946fa8396bd695a1939ef
Publikováno v:
Indian Dermatology Online Journal, Vol 15, Iss 5, Pp 823-827 (2024)
Anti-melanoma differentiation-associated gene-5 antibody (anti-MDA-5 Ab) associated with clinically amyopathic dermatomyositis (CADM) is characterized by vasculopathic ulcers, mechanic’s hands, and progressive interstitial lung disease (ILD). We pr
Externí odkaz:
https://doaj.org/article/9f53e25b64664a0eb6764699e8fa736c
Publikováno v:
Indian Journal of Dermatology, Vol 69, Iss 4, Pp 312-316 (2024)
Background: Chronic spontaneous urticaria (CSU) is a distressing skin condition characterized by the recurrent appearance of itchy hives. A subset of CSU patients remains resistant to conventional treatment with high-dose antihistamines. Tofacitinib,
Externí odkaz:
https://doaj.org/article/b82198e2e39c4bebaebb0de79545d858
Publikováno v:
Indian Journal of Dermatology, Vol 69, Iss 4, Pp 292-295 (2024)
Background: Atopic dermatitis (AD) has a complex etiology that includes Th2 polarization, which is accompanied by the cytokines IL4, IL-5, IL-13, and IL-31, as well as Th17 and Th22, and in chronic lesions, Th1 cells. Tofacitinib inhibits Th1-, Th2-,
Externí odkaz:
https://doaj.org/article/a72c52c717934a2c909b75315074edce
Autor:
Qing Liu, Mengling Liu, Zhiguo Zou, Jinyi Lin, Ningping Zhang, Lin Zhao, Jiahua Zhou, Haojie Zhou, Xin Zhou, Xiaodong Jiao, Yiyi Yu, Tianshu Liu
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-11 (2024)
Abstract Background Treatment strategy against immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) frequently requires other immunosuppressive agents. Tofacitinib is a rapidly acting JAK-STAT inhibitor with proven eff
Externí odkaz:
https://doaj.org/article/0e8938951843488299fc84183f272dff
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology, Vol Volume 17, Pp 1917-1920 (2024)
Hongyan Tan, Bin Zhang, Xiawei Kang, Lvyao Wang, Xiao Qiu, Xiangyu Hu Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400011, People’s Republic of ChinaCorrespondence: Xiangyu Hu, Email 369930758@qq.comPurp
Externí odkaz:
https://doaj.org/article/0bd235703639489c889786bb814566a2